Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 8
Submit an article Journal homepage
643
Views
5
CrossRef citations to date
0
Altmetric
Articles

AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial

Stephanie Sassea German Hodgkin Study Group (GHSG), Cologne, Germany;b Clinic for Hematology, Oncology and Gastroenterology, Maria Hilf Hospital Moenchengladbach, Moenchengladbach, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1080-4606
ORCID Icon,
Paul Jan Bröckelmanna German Hodgkin Study Group (GHSG), Cologne, Germany;c Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Cologne, Germany
,
Jesko Momotowa German Hodgkin Study Group (GHSG), Cologne, Germany;c Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Cologne, Germany
,
Annette Plütschowa German Hodgkin Study Group (GHSG), Cologne, Germany;c Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Cologne, Germany
,
Andreas Hüttmannd Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
,
Nadezda Basarae St. Franziskus Hospital Flensburg, Flensburg, Germany
,
Christian Koeneckef Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
,
Sonja Marting Department of Hematology, Oncology, Palliative Medicine, Robert-Bosch-Hospital, Stuttgart, Germany
,
Martin Bentzh Municipal Hospital Karlsruhe, Karlsruhe, Germany
,
Christina Grosse-Thiei Department of Internal Medicine, Medical Clinic III – Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany
,
Sven Thorspeckenj Hematology, Oncology, Immunology, Hospital Schwabing, München, Germany
,
Maike de Witk Department of Medicine – Hematology, Oncology, Palliative Medicine, Vivantes Hospital Neukölln, Berlin, Germany
,
Carsten Kobea German Hodgkin Study Group (GHSG), Cologne, Germany;l Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
,
Markus Dietleina German Hodgkin Study Group (GHSG), Cologne, Germany;l Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
,
Bastian von Tresckowa German Hodgkin Study Group (GHSG), Cologne, Germany;d Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
,
Michael Fuchsa German Hodgkin Study Group (GHSG), Cologne, Germany;c Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Cologne, Germany
,
Peter Borchmanna German Hodgkin Study Group (GHSG), Cologne, Germany;c Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Cologne, Germany
&
Andreas Engerta German Hodgkin Study Group (GHSG), Cologne, Germany;c Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Cologne, Germany
 show all
Pages 1871-1878 | Received 21 Nov 2021, Accepted 25 Jun 2022, Published online: 18 Jul 2022

References

  • Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol. 2010;28(34):5074–5080.
  • Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
  • Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–2132.
  • Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428–1439.
  • Chiu J, Ernst DM, Keating A. Acquired natural killer cell dysfunction in the tumor microenvironment of classic Hodgkin lymphoma. Front Immunol. 2018;9:267.
  • Porrata LF, Inwards DJ, Micallef IN, et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol. 2002;117(3):629–633.
  • Gordan LN, Sugrue MW, Lynch JW, et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003;31(11):1009–1013.
  • Reusch U, Burkhardt C, Fucek I, et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs. 2014;6(3):728–739.
  • Reiners KS, Kessler J, Sauer M, et al. Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther. 2013;21(4):895–903.
  • Rothe A, Sasse S, Topp MS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024–4031.
  • Bartlett NL, Herrera AF, Domingo-Domenech E, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136(21):2401–2409.
  • Vari F, Arpon D, Keane C, et al. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 2018;131(16):1809–1819.
  • Nieto Y, Banerjee P, Kaur I, et al. Innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma. Proceedings of the 113th Annual Meeting of the American Association for Cancer Research; 2021 Apr 8–13; New Orleans, LA. Philadelphia (PA): AACR; 2022. Abstract number CT003.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.